Axel-Rainer Hanauske, MD, Ph.D., MBA holds a Professorship of Medicine at the Technical University in Munich, Germany and is Board-certified in Internal Medicine, Hematology/Medical Oncology, and Palliative Care. At present, he is a consultant in Oncology and Hematology for several companies and universities focusing on early drug development, translational research and treatment individualisation.
Axel has worked for Lilly since 2006 in various positions in medical management. His roles involved the USA, Europe, Australia/New Zealand, and China. Before he was Chair of the Department of Internal Medicine and Medical Oncology at St. George Hospital, Hamburg, Germany and Deputy Chief of the Division of Hematology and Medical Oncology at the Technical University Munich. He has also held a Professorship at the Catholic University of Leuven, Belgium.
Axel has held positions on the board of several oncology research organisations and study groups, including the EORTC, Central European Society for Anticancer Research (CESAR), and the Early Phase Group of the German Cancer Society.
His research team discovered the clinical activity of pemetrexed/cisplatin in mesothelioma and laid grounds for the development of pemetrexed/cisplatin in non-small cell lung cancer. Axel has authored or co-authored 209 peer-reviewed publications, 167 review presentations and 319 oral or poster presentations.